Clinical Pharmacists’ Knowledge of and Attitudes toward Pharmacogenomic Testing in China

Xiaoyan Nie 1,2, Tong Jia 1, Xiaowen Hu 1, Sicong Li 1, Xinyi Zhang 1, Caiying Wu 1, Yuqing Zhang 1, Jing Chen 1,2, Luwen Shi 1,2,* and Christine Y. Lu 3

1 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
2 International Research Center for Medicinal Administration, Peking University, Beijing 100191, China
3 Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA
* Correspondence: shilu@bjmu.edu.cn; Tel.: +86-10-8280-5019

Abstract: (1) Background: Uptake of pharmacogenomic testing in routine clinical practices is currently slow in China. Pharmacists might play an important role in leveraging care through applying pharmacogenomics, therefore, it is important to better understand clinical pharmacists’ knowledge of and attitudes toward pharmacogenomic testing, which has not been well-studied. (2) Methods: A self-administered survey was developed based on previous knowledge of pharmacogenomic testing and its uptake in China. Participants were recruited through the Committee of Pharmaceutical Affairs Management under the Chinese Hospital Association. (3) Results: A total of 1005 clinical pharmacists completed the questionnaire, among whom 996 (99.10%) had heard of pharmacogenomic testing before participation. More than half of respondents (60.0%, n = 597) rated their knowledge of pharmacogenomic testing as “average”, while 25% rated it “good” or “excellent”. “Guidelines, consensus and treatment paths for disease diagnosis and treatment” (78.7%) were the most preferred sources of information about pharmacogenomic testing. Most respondents (77.0%) believed that pharmacogenomics could “help to improve efficacy and reduce the incidence of adverse reactions”. Our participants also believed that patients would benefit most from pharmacogenomic testing through better prediction of individual drug responses and thus informed treatment decisions. The top challenge for the uptake of pharmacogenomic testing was its high cost or lack of insurance coverage (76.7%). (4) Conclusions: Most Chinese clinical pharmacists who participated in our study had a positive attitude toward pharmacogenomic testing, while the knowledge of pharmacogenomic testing was generally self-assessed as average.

Keywords: pharmacogenomic testing; clinical pharmacist; knowledge; attitude; China

1. Introduction

Pharmacogenomics (PGx) research and its implications in clinical practices have increased in recent years as healthcare moves towards precision medicine [1]. PGx testing is the use of genetic tests to suggest the optimal pharmaceutical therapy for individual patients [2], which has the potential to reduce adverse drug responses and improve drug efficacy. To date, the US Food and Drug Administration (FDA) has approved more than 400 drug labels with information on genomic biomarkers and their relationship with drug exposure, dosage, risk of adverse effects, and clinical response variability [3]. Moreover, the Dutch Pharmacogenetics Working Group (DPWG), the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), and the French National Network (Réseau) of Pharmacogenetics (RNPGx) have provided evidence-based clinical recommendations for PGx practice [4].

Increasing uptake of PGx testing has been most notably witnessed in the fields of oncology and cardiovascular diseases and gradually in the fields of psychiatry [5,6], pain
relief [7], rheumatic immunology [8], and neurology [9,10]. However, in China, PGx testing has yet to be fully incorporated into routine clinical practice.

Clinical pharmacists have unique advantages in managing drug therapies. Previous studies suggested that clinical pharmacists are well-positioned to promote uptake of PGx and leverage care. The American Society of Health-System Pharmacists (ASHP) has also called for “all pharmacists have a responsibility to take a prominent role in the rational, ethical use and clinical application of pharmacogenomic” [11]. However, pharmacists in high-income countries reported limited knowledge of and many concerns about PGx; high costs, limited insurance reimbursement, lack of domestic clinical guidelines, lack of trust in the vendor of PGx results, and fear of discrimination and misinterpretation of test results were among factors commonly recognized to have hindered PGx’s uptake in clinical practices [12]. In 2019, Guo et al. [13] designed a questionnaire to obtain a comprehensive understanding of PGx by physicians, pharmacists, and researchers. However, given its small sample size of pharmacists and the fact that the respondents mainly resided in south-central and south-western regions, such as Hunan Province, and did not distinguish between types of pharmacists, there is a lack of research on the clinical pharmacists’ knowledge of and attitudes toward PGx in China. Thus, this study aimed to explore clinical pharmacists’ attitudes toward and knowledge of PGx testing in China and their views on the main barriers that had hindered uptake of PGx testing.

2. Materials and Methods

2.1. Survey Development

Based on the current use of PGx testing in China and similar studies [14–20] in other countries, we developed a questionnaire inquiring clinical pharmacists’ knowledge of, attitudes toward, and experience with PGx testing. The survey contains 38 questions and takes an estimated 10–15 min to complete. The questionnaire has been mentioned in our previously published study [21]. In this paper, we report findings from the first and third sections (24 questions) of the survey, focusing on the attitude and knowledge of pharmacists. The 14 questions in the survey’s second section pertained to clinical pharmacists’ involvement in PGx testing, which will be presented in another article. If the respondent selected “I volunteer to participate in the study”, all questions should be answered. (More details on the methods can be found in Appendix A).

2.2. Sampling Methods and Data Collection

The sample was recruited through the Committee of Pharmaceutical Affairs Management under the Chinese Hospital Association, the organizer of a training platform for clinical pharmacists. The participants used the “Wenjuanxing” platform (www.wjx.cn (accessed on 10 October 2021)) [22] to complete the electronic questionnaire, which was sent to the working group of the training platform according to the distribution of provinces. The questionnaires answered by clinical pharmacists who met the two inclusion criteria (Appendix A) were included in this study.

The questionnaire was open for 30 days until 12 November 2021. The study was approved by the Institutional Review Boards at Peking University, Beijing, China (IRB 20211100). Respondents who completed the survey received 10 yuan (~US$ 1.48) as compensation for their time.

2.3. Data Analysis

For each question, response frequencies and percentages were described. Factors that might be associated with the knowledge of and attitudes toward PGx testing were analyzed by multivariate logistic regression analysis. Estimates were weighted with a 95% confidence interval provided, where applicable. All statistical analyses were performed using STATA 15.1.
3. Results

3.1. Survey Completion Rates and Inclusion

Our electronic questionnaire had 1560 clicks, however, 555 were excluded as they were from pharmacists who did not work at Chinese tertiary hospitals, or were not clinical pharmacists; questionnaires that were not completed were also excluded. In the end, the survey completion rate was 64.4%, resulting in a total of 1005 clinical pharmacist responses from 31 provinces and autonomous regions were included in the study.

3.2. Respondent Characteristics

Among the total of 1005 clinical pharmacists, 996 (99.1%) had heard of PGx testing before participation (who hereafter would be referred to as the pre-knowns), and nine (0.9 %) had not. Characteristics of study respondents are shown in Table 1 and Figure S1. No significant differences were observed in any baseline characteristics between the total study sample and the pre-knowns. The following results are based on pre-knowns.

Considering that respondents’ willingness to adopt new technologies might impact their attitudes toward PGx testing, a relevant question was included in the questionnaire. Most respondents (80.8%, \( n = 812 \)) selected “aware of the need to change and very comfortable adopting new technologies and adopt new technologies before the average person, but need to see evidence of success before adopting”. Meanwhile, 119 (11.8%) and 74 (7.4%) respondents chose “want to be the first person to try an innovation” and “skeptical of change, only adopt an innovation after it has been tried by the majority”, respectively.

3.3. Knowledge of PGx Testing

Many respondents (59.9%, \( n = 597 \)) rated their knowledge of PGx testing as “average”, while 24.6% rated “good” or “excellent” (Figure 1).

![Knowledge of pharmacogenomic testing](image)

Figure 1. Knowledge of pharmacogenomic testing.

The multivariate analysis for clinical pharmacists’ knowledge with PGx testing showed that clinical pharmacists with the following baseline characteristics showed better self-evaluated knowledge of PGx testing: male (\( p < 0.001 \)), with a master’s degree (\( p < 0.001 \)) or doctoral degree (\( p < 0.001 \)), were associate chief or chief clinical pharmacists (\( p = 0.01 \)) or with a middle-level title (\( p = 0.02 \)), in provinces with high GDP rank (\( p < 0.001 \)), or hold a positive attitudes toward new technologies (\( p < 0.001 \)).

Clinical pharmacists’ knowledge about different PGx-related guidelines, monographs, and databases varied. In general, their knowledge of domestic guidelines or expert consensus was better, with half of the respondents (50.9%, \( n = 507 \)) rating themselves “good” or “excellent” on this aspect of their PGx knowledge. Clinical pharmacists’ knowledge about international guidelines and databases was relatively low, and only 17.5% (\( n = 174 \)), 25.7% (\( n = 256 \)), 23.6% (\( n = 235 \)) rated themselves as having “good” or “excellent” knowledge about ClinGen, PharmGKB, and CPIC, respectively (Figure 2).
Table 1. Characteristics of study respondents.

|                          | All            | Have Heard of Pharmacogenomic Testing Before |
|--------------------------|----------------|---------------------------------------------|
|                          | $n^1$ | %   | $n$  | %   |
| Sum                      | 1005 | 100.0 | 996  | 99.1 |
| Gender                   |       |      |      |      |
| male                     | 244  | 24.3 | 241  | 24.2 |
| Age                      |       |      |      |      |
| $\leq 30$                | 183  | 18.2 | 178  | 17.9 |
| 31–35                    | 472  | 47.0 | 468  | 47.0 |
| 36–40                    | 225  | 22.4 | 225  | 22.6 |
| >40                      | 125  | 12.4 | 125  | 12.6 |
| Highest qualification    |       |      |      |      |
| bachelor degree or below | 332  | 33.0 | 327  | 32.8 |
| master’s degree          | 596  | 59.3 | 592  | 59.4 |
| doctoral degree          | 77   | 7.7  | 77   | 7.7  |
| Overseas education background $^2$ | 7  | 0.7  | 7   | 0.7  |
| for a degree exchange and visit | 50 | 5.0  | 50  | 5.0  |
| Years of work experience $^3$ |       |      |      |      |
| $\leq 5$ years           | 212  | 21.1 | 208  | 20.9 |
| 5–10 years               | 406  | 40.4 | 401  | 40.3 |
| $>$10 years              | 387  | 38.5 | 387  | 38.9 |
| Professional title       |       |      |      |      |
| junior pharmacist or below | 152 | 15.1 | 144  | 14.5 |
| middle level pharmacist  | 633  | 63.0 | 630  | 63.3 |
| associate chief or chief clinical pharmacist | 220 | 21.9 | 182  | 18.3 |
| Relationship between practicing hospital and medical college |       |      |      |      |
| neither affiliated nor teaching hospital | 150 | 14.9 | 144  | 14.2 |
| teaching hospital         | 216  | 21.5 | 213  | 21.4 |
| affiliated hospital $^4$  | 609  | 60.6 | 609  | 61.1 |
| GDP rank of the practicing province |       |      |      |      |
| low                       | 265  | 26.4 | 261  | 26.2 |
| middle                    | 332  | 33.0 | 328  | 32.9 |
| high                      | 408  | 40.6 | 407  | 40.9 |

Annotation: $^1$ N refers to the number of respondents. $^2$ Overseas education background refers to whether respondents have studied abroad or participated in an overseas exchange program. $^3$ Years of work experience refers to the duration of working as a pharmacist. $^4$ The affiliated hospitals are part of the medical school and have affiliation with the medical school, including the affiliated general hospitals that are responsible for the whole clinical teaching (theoretical teaching, clinical internship, and graduation internship) and the affiliated specialized hospitals that are responsible for part of the clinical teaching. $^5$ Teaching hospitals are general hospitals or specialized hospitals that have established stable teaching relationships with medical colleges and universities.
Figure 2. Knowledge about PGx-related guidelines, monographs, and databases.

We analyzed the interactions between the level of knowledge about PGx and of the corresponding guidelines, monographs, and databases. For instance, 53.0% of the respondents who had a good or excellent grasp of the PGx testing also rated themselves as having good or excellent knowledge about the CPIC guidelines, while 88.3% of the respondents who had a lower-than-average knowledge of PGx testing also said that their knowledge about the guidelines was below average. Not surprisingly, respondents who had a higher level of knowledge about PGx testing also had a higher level of knowledge about the corresponding PGx-related guidelines, monographs, and databases \( p < 0.001 \).

The majority (78.7%) of respondents had accessed information about PGx through “Guidelines, consensus and, clinical pathways for disease diagnosis and treatment”, followed by “Academic conference” (64.1%), and “Professional PGx-related guidelines, monographs, or databases” (49.7%).

3.4. Attitudes towards PGx Testing

Respondents generally acknowledged the significance of PGx testing. Most respondents (77.2%) agreed that PGx testing could “help to improve efficacy and reduce the incidence of adverse reactions from drug therapy”. For all questions, more than 50.0% of respondents agreed with the description presented (Figure 3).

Figure 3. Attitudes towards the role and clinical effect of pharmacogenomic testing.

Respondents who were positive toward new technologies were also more positive toward the significance of PGx testing in clinical practices than those who were negative toward novel technologies \( p < 0.001 \). After excluding the influence of the significant factor “attitude towards new technologies” in the multivariate analysis, respondents with “excellent” knowledge of PGx testing were significantly more positive towards PGx testing’s role and clinical impact.

When being asked about the value of PGx in different therapeutic areas, the use of PGx testing in “Targeted Oncology Therapy” was most highly recognized, with more than half of respondents rating the value of PGx as 80–100 in this therapeutic area (Table 2). The association between respondents’ clinical practice specialties and their scoring of the value of PGx testing in different areas shows that clinical pharmacists in oncology departments tended to score oncology therapeutic areas higher than therapeutic areas in which they did not specialize (Table 3).
### Table 2. Value of pharmacogenomic testing in different treatment areas (scale 0–100).

| Areas                     | Medium | 0–20 | 20–40 | 40–60 | 60–80 | 80–100 |
|---------------------------|--------|------|-------|-------|-------|--------|
| (1) Targeted Oncology Therapy | 78.65 ± 22.41 | 31 (3.1%) | 52 (6.2%) | 275 (27.6%) | 541 (54.3%) |
| (2) Cardiovascular disease | 66.80 ± 23.65 | 54 (6.9%) | 213 (21.6%) | 301 (30.3%) |
| (3) Rheumatic immune diseases | 65.51 ± 25.30 | 69 (6.9%) | 215 (21.6%) | 302 (30.3%) |
| (4) Psychiatric and neurologic conditions | 64.51 ± 25.02 | 75 (7.5%) | 212 (21.3%) | 284 (28.5%) |
| (5) Infectious Diseases | 59.11 ± 26.31 | 97 (9.7%) | 251 (25.2%) | 225 (22.6%) |
| (6) Pain Treatment | 58.79 ± 25.47 | 99 (9.9%) | 271 (27.2%) | 204 (20.5%) |
| (7) Other fields | 47.83 ± 28.42 | 216 (22%) | 254 (25.5%) | 129 (13%) |

### Table 3. Scores of clinical pharmacists from different departments on the value of pharmacogenomic testing in different therapeutic areas (the most relevant departments to the disease areas were presented).

| Department | Area | Targeted Oncology | Cardiovascular | Rheumatic Immune | Psychiatry and Neurology | Infectious Diseases | Pain Treatment |
|------------|------|-------------------|----------------|-----------------|--------------------------|---------------------|---------------|
| Card       |      | 77.40 ± 24.11     | 70.84 ± 25.09 | 63.35 ± 25.90   | 64.74 ± 22.43            | 60.54 ± 26.09       | 60.74 ± 25.90 |
| Cere/Neur  |      | 70.99 ± 22.02     | 63.61 ± 21.23 | 64.87 ± 24.33   | 65.77 ± 20.34            | 57.64 ± 24.30       | 56.74 ± 22.60 |
| Onco       |      | 83.59 ± 21.12     | 61.75 ± 26.37 | 60.10 ± 26.38   | 57.61 ± 26.98            | 54.75 ± 27.40       | 55.55 ± 26.98 |
| Psy        |      | 73.86 ± 26.24     | 60.93 ± 29.91 | 63.57 ± 31.50   | 72.14 ± 23.70            | 55.79 ± 33.47       | 63.36 ± 32.17 |
| Rheu       |      | 84.29 ± 14.57     | 67.14 ± 22.91 | 73.00 ± 17.15   | 68.71 ± 23.31            | 44.00 ± 25.01       | 61.00 ± 21.32 |
| Infe       |      | 83.20 ± 22.67     | 70.80 ± 24.90 | 69.25 ± 28.36   | 70.40 ± 23.95            | 66.00 ± 25.26       | 68.00 ± 18.60 |
| Pain       |      | 76.38 ± 34.72     | 64.54 ± 29.57 | 64.46 ± 31.68   | 65.54 ± 30.69            | 57.69 ± 29.05       | 53.31 ± 34.67 |

Annotation: ¹ Cardiovascular (Card), Cerebrovascular/Neurology (Cere/Neur), Oncology (Onco), Psychiatry (Psy), Rheumatology (Rheu), Anti-infectives (Infe). ² The association between respondents’ clinical practice specialties with their scoring of the value of PGx testing in the same areas was tested by Kruskal-Wallis H Test, which showed that the oncology pharmacist–oncology PGx association was the only one that was statistically significant.

Half of respondents (50.9%, n = 507) agreed that patients would benefit most from PGx testing if results were used to help predict poor response to a medication, followed by those who used test results to help predict possible side effects (23.1%, n = 230) and those who used test results to guide the determination of the initial dose (13.7%, 136). However, there were four respondents (0.4%) who thought PGx testing would not benefit patients at all.

#### 3.5. Barriers of Developing PGx Testing

Our participants suggested that the top three challenges for increasing uptake of PGx testing were its high cost or lack of insurance coverage (76.7%, n = 764), the lack of trained professionals (65.9%, n = 656), and lack of relevant knowledge (53.7%, n = 535). Other challenges perceived by many of the participants included lack of testing devices (46.6%, n = 464) and shortage of recommendations by guidelines or consensus (42.2%, n = 420).

#### 3.6. Others

##### 3.6.1. Responsibilities of Pharmacists in PGx Testing

“Make recommendations to physicians on drug selection, dosage, and monitoring based on the results of PGx testing” (94.8%, n = 944) and “Interpret PGx test results to physicians and patients” (87.5%, n = 871) were the two most important responsibilities identified by the pre-knowns. There were also four clinical pharmacists who suggested
that other responsibilities of pharmacists in PGx testing might include “Conduct related research” and “Generate clinical evidence of PGx testing”.

3.6.2. Willingness to Participate in PGx Trainings

Among all respondents, 906 (90.2%) suggested that they were willing to participate in PGx training if provided, while 16 (1.6%) showed no interest. Favored training modes were “Short-term intensive training” (57.3%), “Online video courses” (56.2%), “Expert lectures” (52.3%), and “Academic conferences” (52.0%).

4. Discussion

To assess clinical pharmacists’ knowledge of and attitudes toward PGx testing, we conducted this survey among clinical pharmacists practicing at tertiary hospitals across mainland China. We found that most Chinese clinical pharmacists who participated in our survey had a relatively good understanding of and positive attitudes toward PGx testing compared with results presented by similar studies in Saudi Arabia [23] (knowledge score for all participants was 2.4 out of 5.0), Japan [24] (only 12.5% respondents showed a good understanding of PGx testing), Thailand [25], Netherlands [26], and Australia [27,28] (6–21% pharmacists have knowledge about PGx testing).

Among the 1005 respondents included in the study, 99.1% (n = 996) were pre-knowns, i.e., respondents who had heard of PGx testing before our survey. A quarter of the pre-knowns had a good grasp of PGx testing, which was higher than results from high-income countries (5.0% in the US and 12.5% in Japan) [24]. This may be explained by our study sample having a general tendency to accept new technologies compared with the general pharmacist population in China, which might have led to an over-estimation of knowledge about PGx testing. Unlike western countries, where pharmacy services are mainly provided in community pharmacies [29], in China, pharmacy services are mainly provided in secondary and tertiary hospitals. Secondary hospitals located in counties or districts mainly provide medical services to local residents. Tertiary hospitals are the highest-level hospitals in China and include national, provincial, municipal, and teaching hospitals [30]. Our respondents all worked at tertiary hospitals, with relatively easy access to high-end healthcare resources and innovative care [31]. They might thus have a more positive attitude toward PGx testing and were more willing to practice it than pharmacists who worked in medical institutions of other tiers (i.e., primary care facilities and secondary hospitals) in China.

The 996 pre-knowns generally had a positive attitude towards PGx testing. Respondents who had a higher level of knowledge about PGx testing were more likely to hold a positive attitude toward it. In Japan [24], surveyed pharmacists were more positive about the significance of PGx testing in improving (95.3%) or attenuating treatment efficacy (91.7%) compared with our respondents. A study in Egypt [32] also showed a higher proportion of respondents (95.2% vs. 59.0%) who agreed that PGx testing would improve pharmacists’ capacity to control expenditures on drug therapies. PGx testing also appeared to be valued differentially in different therapeutic areas. Our respondents assigned the highest value to the use of PGx testing in targeted oncology therapies. Furthermore, clinical pharmacists in oncology department tended to score oncology therapeutic areas higher than therapeutic areas in which they did not specialize, which may suggest that specialty-targeted pharmacogenomic training would be more helpful for clinical pharmacists.

The high cost or lack of insurance coverage of PGx tests, lack of trained professionals, and lack of relevant knowledge were cited as the three most important factors hindering the uptake of PGx testing. In a Japanese study [24] in 2021, “not covered by insurance”, “requiring expenses for analysis”, and “lack of workforce” were also the three main factors that hampered the use of PGx testing in routine clinical practices. In Thailand, most respondents (74.0%) felt extremely or moderately concerned about the reimbursement for PGx testing [25]. To promote the use of PGx testing, China has considered incorporating PGx testing into health insurance schemes. Beijing, as a pilot city, introduced the unified pricing and insurance coverage for PGx testing for tumors (which included pharmacoge-
nomic/germline testing in addition to somatic testing) for the first time in 2019 [33], with the reimbursement rate as high as 90.0%. For cancer patients with their medical insurance registered in Beijing, PGx testing for tumors can be carried out at any hospital in Beijing and reimbursed by their health insurance. On the other hand, “Guidelines, consensus, and clinical pathways for disease diagnosis and treatment” were the most preferred approaches to learn about PGx testing in this study. In China, there are only six domestic consensus or guidelines [34–39], a number much smaller than in the United States and other developed countries. The domestic consensus and guidelines are developed by concerned associations and the National Health and Family Planning Commission, and they cover cardiovascular, oncology, and specific assays as well as provide information on evidence-based and result interpretation of PGx testing for specific genes [4,40–42]. Given that our results showed that respondents’ understanding of domestic guidelines and expert consensus was better than their knowledge of the three well-known international standard guidelines or databases (CPIC, PharmGKB, ClinGen), the lack of domestic guidelines might have impacted the uptake of PGx testing. Likewise, Guo and colleagues [13] conducted a survey on PGx use among physicians, pharmacists, and researchers and found that over 50% of pharmacists recognized the importance of PGx testing. However, the pharmacists also perceived that the lack of clinical studies and domestic guidelines were the main barriers to increasing uptake of PGx testing, which is consistent with our findings.

The vast majority of respondents hoped to receive more training in PGx testing in the future, with “Short-term intensive training”, “Online video courses” and “Expert lectures” being the three most popular approaches. In other studies, online courses were also a popular way of training, which may be due to the fact that pharmacists had a busy schedule, and online training and materials allowed for swift scheduling. In comparison, the preferred training modes by pharmacists in Malaysia [43] were undergraduate PGx education (54.0%) and prior PGx education (38.9%). A study in Australia [27] showed that most respondents believed that the best setting to educate pharmacists was at university during a Bachelor of Pharmacy degree (66.7%) and after registration, as workshops and seminars which contributed to pharmacists’ continuing education program (79.0%). However, only 10.7% and 14.4% had studied PGx testing-related courses in undergraduate and graduate programs in our results, respectively. A similar tendency was also found in the US and Japan [24], with 26.1% of the surveyed pharmacists learning about PGx in their undergraduate courses in the US, compared with 12.9% in Japan [24] and 31.6% in Australia [27]. Future educational efforts should consider the above findings to train clinical pharmacists about PGx testing and incorporate PGx into undergraduate and graduate courses.

Our survey has some limitations. Firstly, the respondents in our study were all practicing at tertiary hospitals, who generally had a higher level of knowledge than professionals practicing at health facilities of other tiers. Although most PGx tests were conducted in tertiary hospitals [30], our results may not represent the knowledge of and attitudes toward PGx testing of the broader pharmacist population across China. Secondly, the knowledge of PGx testing was assessed through self-evaluation, which might be vulnerable to social desirability bias [44] and not truly reflect the knowledge level of Chinese clinical pharmacists on PGx testing.

5. Conclusions
This study surveyed clinical pharmacists across China and found that most Chinese clinical pharmacists who responded had a positive attitude toward PGx testing. However, they were less familiar with international standard guidelines and databases about PGx testing. The high cost of testing, shortage of relevant professionals, and lack of insurance coverage were perceived as main challenges that hindered uptake of PGx testing in routine clinical practices. Future courses and trainings materials for health professionals should incorporate information about PGx and PGx testing.
Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jpm12081348/s1, Figure S1: Distribution of top ten provinces and departments.

Author Contributions: Conceptualization, X.N. and C.Y.L.; methodology, X.N. and C.Y.L.; software, X.H. and T.J.; validation, X.H., X.N. and C.Y.L.; formal analysis, X.H. and T.J.; investigation, T.J., S.L., X.Z., C.W., Y.Z. and J.C.; resources, X.N. and L.S.; data curation, X.H. and T.J.; writing—original draft preparation, X.H. and T.J.; writing—review and editing, X.H., X.N., L.S. and C.Y.L.; visualization, X.H. and X.N.; supervision, X.N. and L.S.; project administration, Y.Z., X.N. and L.S.; funding acquisition, X.N. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by National Natural Science Foundation of China to Xiaoyan Nie (grant no. 81803497).

Institutional Review Board Statement: The study was approved by the Institutional Review Boards at Peking University, Beijing, China (IRB 2021100).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: The authors would like to thank all pharmacists who responded to this survey, the Pharmaceutical Affairs Management Professional Committee of the Chinese Hospital Association who support the collection of samples, and Yuxuan Zhao, Yuchun Cai, Congxiao Han, Xiaodong Guan and Jiancun Zhen for data collection. A special thank you to Huang Qianyu Li for language correction.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A

Details of the methods.

1. Survey Development.

We developed a questionnaire inquiring about clinical pharmacists’ knowledge of, attitudes toward, and experience with PGx testing. We first developed an initial draft of the questionnaire based on the current use of PGx testing in China and similar studies in other countries [14–20]. The initial questionnaire was also developed based on previous studies on the use of PGx testing in other countries. Next, we invited four PGx experts in China to review the primary items to provide feedback and suggest necessary changes. The survey was then piloted among 20 clinical pharmacists not included in the final study sample to establish the questionnaire’s reliability. The final survey contained 38 questions, requiring an estimated 10–15 min to complete. In this paper, we report findings from the first five parts (24 questions) of the survey focusing on the attitude and knowledge of pharmacists. The remaining 14 questions related to clinical pharmacists’ involvement in PGx tests will be presented in another article. Questions were divided into five sections: (1) respondent characteristics (14 items); (2) knowledge of PGx testing (3 items), (1) explored pharmacists’ knowledge of PGx testing, (2) investigated pharmacists’ knowledge of the guidelines and databases, and (3) collected the most common ways for pharmacists to learn about PGx; (3) attitudes towards PGx testing (3 items), (1) explored the clinical effect of PGx testing, (2) value of PGx testing in different therapeutic areas, and (3) patients who might benefit most from PGx testing; (4) barriers to uptake of PGx testing (1 item); and (5) responsibilities of pharmacists in performing PGx testing and willingness to attend relevant training (3 items). Pharmacists’ attitudes toward PGx testing were measured on a 5-point Likert scale, while evaluations about clinical values were measured on a percentile scale. If the respondent selected “I volunteer to participate in the study”, all questions should be answered.

2. Sampling methods and data collection.

The sample was recruited through the Committee of Pharmaceutical Affairs Management under the Chinese Hospital Association, which organized a platform for clinical pharmacist training, and the pharmacists involved in the training were distributed in
22 provinces, 5 autonomous regions, and 4 municipalities directly under the central government in China, and their working years and departments were comprehensively distributed, which provided a suitable group of clinical pharmacists for survey in this study.

The sample size was calculated using Cochran’s formula for descriptive cross-sectional studies:

\[ n = \frac{Z^2 \sigma_p (1 - \sigma_p)}{E^2} \]

Of which, the value of \( \alpha \) and \( Z_{\alpha/2} \) was considered 0.05 and 1.96, and \( \sigma_p \) and \( E \) were regarded to be 0.3 and 0.03, respectively. The primary sample was calculated as eight hundred and ninety-six. Assuming a 90% response rate, the final sample size was nine hundred and ninety-six samples.

The participants entered an online professional survey platform named “Wenjuanxing” platform (www.wjx.cn (accessed on 10 October 2021)) [22] to complete electronic questionnaires. This platform is widely used in many epidemiological surveys [13,45,46] and is a popular, powerful, and personalized questionnaire design system that allows simultaneous data collection and analysis. The electronic questionnaires were dispensed freely in the working group of the clinical pharmacist training platform according to the distribution of provinces. The questionnaires answered by clinical pharmacists who met the following criteria were included in this study: (1) working in the capital cities and sub-provincial cities of each province, in the capital cities of the five autonomous regions or the four municipalities directly under the central government; and (2) working in tertiary hospitals.

The first invitation was sent on 14 October 2021, and the questionnaire was then sent to clinical pharmacists by “Wenjuanxing” for data collection. The questionnaire was open for 30 days until 12 November 2021. The study was approved by the Institutional Review Boards at Peking University, Beijing, China (IRB 2021100). Respondents who completed the survey received 10 yuan (~US$ 1.48) as compensation for their time.

3. Data analysis.

For each question, response frequencies and percentages were described. Provinces, where the pharmacists practiced, were sectioned into three groups according to their GDP rank within the country: (1) provinces with low GDP, which included Gansu (GS), Hainan (HaiN), Heilongjiang (HLJ), Jilin (JL), Neimenggu (NMG), Ningxia (NX), Qinghai (QH), Shanxi (S1X), Tianjin (TJ), Xinjiang (XJ), and Xizang (XZ); (2) provinces with middle GDP, which consisted of Anhui (AH), Beijing (BJ), Chongqing (CQ), Guangxi (GX), Guizhou (GZ), Hebei (HeB), Jiangxi (JX), Liaoning (LN), Shaanxi (SX1), and Yunnan (YN); and (3) provinces with high GDP, spanning Fujian (FJ), Guangdong (GD), Henan (HeN), Hebei (HeB), Hunan (HuN), Jiangsu (JS), Shandong (SD), Shanghai (SH), Sichuan (SC), and Zhejiang (ZJ). Factors that might be associated with the knowledge of and attitude toward PGx testing were analyzed by multivariate logistic regression analysis. Estimates were weighted and a 95% confidence interval was provided where applicable. All statistical analyses were performed using STATA 15.1.

References
1. Collins, F.S.; Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 2015, 372, 793–795. [CrossRef] [PubMed]
2. Haga, S.B.; Burke, W.; Ginsburg, G.S.; Mills, R.; Agans, R. Primary care physicians’ knowledge of and experience with pharmacogenetic testing. Clin. Genet. 2012, 82, 388–394. [CrossRef] [PubMed]
3. Klein, P.M.W.-C.; Russ, T.E.; Altman, R.B. PharmGKB. 2022. Available online: https://www.pharmgkb.org/ (accessed on 19 August 2022).
4. Abdullah-Koolmees, H.; van Keulen, A.M.; Nijenhuis, M.; Deneer, V.H.M. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPgx Guidelines. Front. Pharmacol. 2020, 11, 595219. [CrossRef] [PubMed]
5. Manchia, M.; Pisanu, C.; Squassina, A.; Carpinello, B. Challenges and Future Prospects of Precision Medicine in Psychiatry. Pharm. Pers. Med. 2020, 13, 127–140. [CrossRef]
6. Fabbi, C.; Crisafulli, C.; Calabro, M.; Spina, E.; Serretti, A. Progress and prospects in pharmacogenetics of antidepressant drugs. Expert Opin. Drug Metab. Toxico. 2016, 12, 1157–1168. [CrossRef]
7. Sadhasivam, S.; Chidambaran, V. Pharmacogenomics of opioids and perioperative pain management. *Pharmacogenomics* **2012**, *13*, 1719–1740. [CrossRef]
8. Siva, C.; Yokoyama, W.M.; McLeod, H.L. Pharmacogenetics in rheumatology: The prospects and limitations of an emerging field. *Rheumatology* **2002**, *41*, 1273–1279. [CrossRef]
9. Cacabelos, R. Pharmacogenomics and therapeutic prospects in dementia. *Eur. Arch. Psychiatry Clin. Neurosci.* **2008**, *258* (Suppl. 1), 28–47. [CrossRef]
10. Szoeke, C.E.; Newton, M.; Wood, J.M.; Goldstein, D.; Berkovic, S.F.; O’Brien, T.J.; Sheffield, L.J. Update on pharmacogenetics in epilepsy: A brief review. *Lancet Neurol.* **2006**, *5*, 189–196. [CrossRef]
11. Haidar, C.E.; Petry, N.; Oxencis, C.; Douglas, J.S.; Hoffman, J.M. ASHP Statement on the Pharmacist’s Role in Clinical Pharmacogenetics. *Am. J. Health Syst. Pharm.* **2022**, *79*, 704–707. [CrossRef]
12. Abou Diwan, E.; Zeitoun, R.I.; Abou Haidar, L.; Cascorbi, I.; Khoeiry Zgheib, N. Implementation and obstacles of pharmacogenetics in clinical practice: An international survey. *Br. J. Clin. Pharmacol.* **2019**, *85*, 2076–2088. [CrossRef] [PubMed]
13. Guo, C.; Hu, B.; Guo, C.; Meng, X.; Kuang, Y.; Huang, L.; Wang, D.; Xu, K.; Zhao, Y.; Yang, G.; et al. A Survey of Pharmacogenomics Testing Among Physicians, Pharmacists, and Researchers From China. *Front. Pharmacol.* **2021**, *12*, 682020. [CrossRef] [PubMed]
14. Muflih, S.; Al-Husein, B.A.; Karaseh, R.; Alzoubi, K.H. Physicians’ Attitudes and Ethical Obligations to Pharmacogenomic Testing. *J. Multidiscip. Healthc.* **2020**, *13*, 249–258. [CrossRef] [PubMed]
15. Albassam, A.; Alshammari, S.; Ouda, G.; Koshy, S.; Awad, A. Knowledge, perceptions and confidence of physicians and pharmacists towards pharmacogenetics practice in Kuwait. *PLoS ONE* **2018**, *13*, e0203033. [CrossRef]
16. Tuteja, S.; Haynes, K.; Zayac, C.; Sprague, J.E.; Bernhardt, B.; Pyeritz, R. Community pharmacists’ attitudes towards clinical utility and ethical implications of pharmacogenetic testing. *Pers. Med.* **2013**, *10*, 793–800. [CrossRef]
17. de Denus, S.; Letarte, N.; Hurlimann, T.; Lambert, J.P.; Lavoie, A.; Robb, L.; Sheehan, N.L.; Turgeon, J.; Vadrnais, B. An evaluation of pharmacists’ expectations towards pharmacogenomics. *Pharmacogenomics* **2013**, *14*, 165–175. [CrossRef]
18. Bonter, K.; Desjardins, C.; Currier, N.; Pun, J.; Ashbury, F.D. Personalised medicine in Canada: A survey of adoption and practice in oncology, cardiology and family medicine. *BMJ Open* **2011**, *1*, e000110. [CrossRef]
19. Faragher, E.A.; Eddy, C.; Newman, W.; Qasim, E.; Tricker, K.; Elliott, R.A.; Payne, K. Patients’ and healthcare professionals’ views on pharmacogenetic testing and its future delivery in the NHS. *Pharmacogenomics* **2007**, *8*, 1511–1519. [CrossRef]
20. McCullough, K.B.; Formea, C.M.; Berg, K.D.; Burzynski, J.A.; Cunningham, J.L.; Ou, N.N.; Rudis, M.I.; Stollings, J.L.; Nicholson, W.T. Assessment of the pharmacogenomics educational needs of pharmacists (Chinese version). *Am. J. Pharm. Educ.* **2011**, *75*, 51. [CrossRef]
21. Hu, X.; Jia, T.; Zhang, X.; Wu, C.; Zhang, Y.; Chen, J.; Guan, X.; Shi, L.; Lu, C.Y.; Nie, X. Clinical Pharmacists’ Involvement in Pharmacogenomics Testing and Related Services in China. *J. Pers. Med.* **2022**, *12*, 1267. [CrossRef]
22. Xing, W.J. More Than Questionnaires/Online Exams. Available online: https://www.wxj.cn/ (accessed on 26 July 2022).
23. Bagher, A.M.; Neamatallah, T.; Balto, G.; Almikhy, L.; Almutairi, S.S.; Abushal, M.O.; Baghlaf, K.; Bagher, S.M. Knowledge, perception, and confidence of hospital pharmacists toward pharmacogenetics in Jeddah, Kingdom of Saudi Arabia. *Saudi Pharm. J.* **2021**, *29*, 53–58. [CrossRef] [PubMed]
24. Tsuji, D.; Saito, Y.; Mushiroda, T.; Miura, M.; Hira, D.; Terada, T. Results of a nationwide survey of Japanese pharmacists regarding the application of pharmacogenomic testing in precision medicine. *J. Clin. Pharm. Ther.* **2021**, *46*, 649–657. [CrossRef]
25. Karuna, N.; Tragulpiankit, P.; Mahasirimonkol, S.; Chumnumwat, S. Knowledge, attitude, and practice towards pharmacogenetics among hospital pharmacists in Thailand. *Pharmacogenomics* **2013**, *14*, 793–800. [CrossRef]
26. Bank, P.C.; Sven, J.J.; Guchelaar, H.J. A nationwide survey of pharmacists’ perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations. *Pharmacogenomics* **2017**, *18*, 215–225. [CrossRef]
27. McMahon, T.; Tucci, J. The perceptions of pharmacists in Victoria, Australia on pharmacogenetics and its implications. *Pharm. Pract.* **2011**, *9*, 141–147.
28. Pearce, A.; Terrill, B.; Alffenaar, J.W.; Patanwala, A.E.; Kummerfeld, S.; Day, R.; Young, M.A.; Stocker, S.L. Pharmacogenomic testing: Perception of clinical utility, enablers and barriers to adoption in Australian hospitals. *Intern. Med. J.* **2022**, *52*, 1135–1143. [CrossRef] [PubMed]
29. Hepler, C.D.; Strand, L.M. Opportunities and responsibilities in pharmaceutical care. *Am. J. Hosp. Pharm.* **1990**, *47*, 533–543. [CrossRef]
30. Guo, X.; Yao, D.; Liu, J.; Huang, Y.; Wang, Y.; Yao, W. The current status of pharmaceutical care provision in tertiary hospitals: Results of a cross-sectional survey in China. *BMC Health Serv. Res.* **2020**, *20*, 518. [CrossRef]
31. Jiang, X.-H. Survey on Hospital Pharmaceutical Care in China and the Status Quo of Clinical Pharmacy Practice(Part 2): Survey on Status Quo of Clinical Pharmacy Practice. *China Pharm.* **2009**, *20*, 1030–1032.
32. Nagy, M.; Lynch, M.; Kamal, S.; Mohamed, S.; Hadad, A.; Abouelnaga, S.; Aquilante, C.L. Assessment of healthcare professionals’ knowledge, attitudes, and perceived challenges of clinical pharmacogenetic testing in Egypt. *Pers. Med.* **2020**, *17*, 251–260. [CrossRef]
33. Beijing Municipal Medical Insurance Bureau. Notice on Standardizing Adjustment of the Price Items of Pathology and Other Medical Services. Available online: http://ybj.beijing.gov.cn/zwgg/2020_zcwwj/202002/20200211_1627892.html (accessed on 26 May 2022).
34. Expert Committee on Rational Drug Use, National Health and Family Planning Commission; Hypertension Committee of Chinese Physicians Association. Guide to the Rational Use of Drugs for Hypertension (2nd edition) (Chinese version). *Chin. J. Front. Med. Sci. (Electron. Version)* 2017, 9, 28–126. [CrossRef]

35. Chinese Physicians Association, Cardiovascular Medicine Branch; Chinese Stroke Association; International Vascular Federation China. Expert consensus on the treatment of people with intolerance and low responsiveness to commonly used oral antplatelet agents (Chinese version). *JF Chin. J. Interv. Cardiol.* 2021, 29, 241–250. [CrossRef]

36. Chinese Society of Cardiothoracic and Vascular Anesthesia. Expert advice on gene polymorphisms and the clinical use of antithrombotic drugs (Chinese version). *JF Fujian Med. J.* 2017, 39, 9–19.

37. China Association of Pharmaceutical Education, China Rational Clinical Drug Use Committee; Hypertension Branch of China Healthcare International Exchange Promotion Association; Perinatal Nutrition and Metabolism Committee of China Maternal and Child Health Association; Committee of Therapeutic Drug Monitoring Research, Chinese Society of Pharmacology; Neurology Committee of China Medical Education Association; Precision Nutrition Committee of China Nutrition and Health Food Association; China Pharmacists Association; China Pharmacists Branch of Home Pharmacy Service; Expert Committee on Drugs and Health Products, Health China Research Center. Multidisciplinary Expert Consensus on Rational Clinical Folic Acid Supplementation in China (Chinese version). *JF Her. Med.* 2021, 40, 1–19. [CrossRef]

38. China’s Health and Family Planning Commission. Interim Guidelines of Detection Techniques for Drug Metabolizing Enzymes and Acting Target Genes (Chinese version). *JF Pract. J. Organ Transplant.* 2015, 3, 257–267. [CrossRef]

39. China’s Health and Family Planning Commission. The Interim Guidelines of Detection Techniques of Individualized Antineoplastic Therapies (Chinese version). *JF Pract. J. Organ Transplant (Electron. Version)* 2015, 3, 257–267.

40. Clinical Pharmacogenetics Implementation Consortium. Available online: https://cpicpgx.org/ (accessed on 26 May 2022).

41. Wang, Y.-T.; Merl, M.-Y.; Yang, J.; Zhu, Z.-X.; Li, G.-H. Opportunities for pharmacists to integrate pharmacogenomics into clinical practice. *Pharm. J.* 2020, 20, 169–178. [CrossRef]

42. Yoon, D.Y.; Lee, S.; Ban, M.S.; Jang, I.-J.; Lee, S. Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels. *Transl. Clin. Pharmacol.* 2020, 28, 189–198. [CrossRef]

43. Bannur, Z.; Bahaman, S.; Salleh, M.Z.; Teh, L.K. Pharmacogenomics Based Practice in Malaysia: The Attitude, Knowledge and Adoption by the Healthcare Professionals. *IIUM Med. J. Malays.* 2014, 13. [CrossRef]

44. Althubaiti, A. Information bias in health research: Definition, pitfalls, and adjustment methods. *J. Multidiscip. Healthc.* 2016, 9, 211–217. [CrossRef]

45. Liang, D.; Fan, G. Social Support and User Characteristics in Online Diabetes Communities: An in-Depth Survey of a Large-Scale Chinese Population. *Int. J. Environ. Res. Public Health* 2020, 17, 2806. [CrossRef] [PubMed]

46. Zhang, W.-R.; Wang, K.; Yin, L.; Zhao, W.-F.; Xue, Q.; Peng, M.; Min, B.-Q.; Tian, Q.; Leng, H.-X.; Du, J.-L.; et al. Mental Health and Psychosocial Problems of Medical Health Workers during the COVID-19 Epidemic in China. *Psychother. Psychosom.* 2020, 89, 242–250. [CrossRef] [PubMed]